Synthesizing Best Practice to Accelerate Access to Emerging HIV Prevention Modalities
综合最佳实践以加速获得新兴艾滋病毒预防方式
基本信息
- 批准号:10361470
- 负责人:
- 金额:$ 68.75万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-04-20 至 2025-02-28
- 项目状态:未结题
- 来源:
- 关键词:AIDS preventionAddressAdherenceAgeBehaviorCenters for Disease Control and Prevention (U.S.)CharacteristicsClinicClinicalClinical TrialsCollaborationsCommunicable DiseasesCountryCountyDataData CollectionData ReportingDevelopmentDiffusionDrug Delivery SystemsDrug FormulationsEligibility DeterminationEnsureEpidemicEthnic OriginFormulationFundingFutureGenderGeographic LocationsGeographyGoalsGuidelinesHIVHealthIndividualInfrastructureInterventionKnowledgeLiteratureMeasuresMedicaidMethodsModalityModelingMonitorOnline SystemsOralOutcomeOutputPatientsPhasePoliciesPopulationPreventionPrevention strategyPrimary Health CareProcessProviderPublic HealthRaceResearchResearch PersonnelSchoolsSeminalService delivery modelSiteSpecific qualifier valueSpeedStandardizationSystemTelemedicineTestingTheoretical modelTimeTo specifyTrainingWorkbasebiobehaviorclinical developmentclinical practiceclinical research sitedata standardsdesignevidence baseflexibilityfuture implementationhealth equityhealth equity promotionimplementation effortsimplementation fidelityimplementation outcomesimplementation scienceimplementation toolimprovedinnovationnovelpatient populationpre-exposure prophylaxisprevention serviceprogramsresponsescreeningservice deliverysexual identitysuccesstooluptake
项目摘要
7. PROJECT SUMMARY/ABSTRACT
There are a myriad of new HIV pre-exposure prophylaxis (PrEP) drug formulations and delivery modalities
under clinical development, and it is expected that a range of biomedical HIV prevention options will soon be
available. To enable these options to have maximum public health impact there is an urgent need to create
biobehavioral infrastructure (i.e., empirically validated knowledge, guidelines, and tools) that will: a) allow the
integration of these new options into existing PrEP delivery systems; b) support adherence and retention in an
emerging HIV prevention service system; and c) promote health equity by ensuring that new prevention
options expand HIV prevention coverage to highest priority populations. However, limited research exists that
integrates lessons from existing implementation efforts for oral PrEP and develops data-driven tools that can
be used by research and clinical practice to accelerate diffusion of proven prevention strategies. In response to
that need, the specific aims of this project are to: (1) Synthesize intervention components of PrEP service
delivery models in seven federally designated Ending the HIV Epidemic (EtHE) hotspot counties across the
US, representing diverse geographical contexts, patient populations, and delivery settings; (2) Operationalize
a set of PrEP service delivery process and outcome metrics than can be used to assess fidelity to service
delivery models for daily oral PrEP and emerging modalities and measure progress toward enhancing
biomedical prevention uptake, persistence, and equitable coverage; and (3) Define universal and modality-
specific pre-implementation and implementation activities necessary for settings to integrate emerging
prevention options into clinical practice. This project builds on the past work of the investigative team in oral
PrEP demonstration and implementation projects, development/testing of novel prevention modalities, and
dissemination of evidence-based implementation tools for clinical practice. To accomplish our aims, we will
apply two seminal theoretical models from the implementation science literature, and collaborate with seven
clinical partners in seven EtHE hotspots across the US, as well as a CDC-funded Capacity Building Assistance
(CBA) provider who delivers PrEP training and technical assistance to sites across the country. The knowledge
generated by this project will not only advance the field of implementation science, but also create tangible
tools that can help clinics, heath systems, and policy decision makers improve PrEP implementation outcomes
at a population level. This project has the potential to make a significant and sustained impact on the quality of
future implementation efforts, and the speed with which new modalities are effectively disseminated to highest
priority populations.
7.项目总结/摘要
有无数新的艾滋病毒暴露前预防(PrEP)药物配方和交付方式
正在临床开发中,预计一系列生物医学艾滋病毒预防方案将很快被
available.为了使这些选择能够产生最大的公共卫生影响,迫切需要建立
生物行为基础结构(即,经验验证的知识,指导方针和工具),将:a)允许
将这些新选项整合到现有的PrEP提供系统中; B)支持在一个
新的艾滋病毒预防服务系统;以及c)通过确保新的预防措施,
将艾滋病毒预防覆盖面扩大到最优先的人群。然而,有限的研究表明,
整合现有实施工作的经验教训,为口头PrEP和开发数据驱动的工具,可以
在研究和临床实践中使用,以加速已证明有效的预防战略的传播。响应于
该项目的具体目标是:(1)综合PrEP服务的干预成分
在全国七个联邦指定的结束艾滋病毒流行(EtHE)热点县的交付模式
美国,代表不同的地理环境、患者人群和分娩环境;(2)手术
一套PrEP服务交付流程和结果指标,可用于评估服务保真度
每日口服PrEP和新兴模式的交付模式,并衡量提高
生物医学预防的吸收、持久性和公平覆盖率;以及(3)界定普遍性和模式-
具体的实施前和实施活动,
预防方案纳入临床实践。该项目建立在调查小组过去在口头
PrEP示范和实施项目,开发/测试新的预防模式,以及
传播用于临床实践的循证实施工具。为了实现我们的目标,我们将
应用实施科学文献中的两个开创性理论模型,并与七个
美国七个EtHE热点地区的临床合作伙伴,以及CDC资助的能力建设援助
(CBA)提供者谁提供PrEP培训和技术援助的网站在全国各地。知识
该项目产生的技术不仅将推进实施科学领域,而且还将创造有形的
可以帮助诊所、卫生系统和政策决策者改善PrEP实施结果的工具
在人口水平上。该项目有可能对质量产生重大和持续的影响,
未来的执行工作,以及新模式有效传播到最高层的速度,
优先人群。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Sarit A Golub其他文献
Sarit A Golub的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Sarit A Golub', 18)}}的其他基金
Trauma-Informed Investigation of TGNBI Experiences in HIV Stigma Research
TGNBI 在 HIV 耻辱研究中的经历的创伤知情调查
- 批准号:
10646313 - 财政年份:2022
- 资助金额:
$ 68.75万 - 项目类别:
Trauma-Informed Investigation of TGNBI Experiences in HIV Stigma Research
TGNBI 在 HIV 耻辱研究中的经历的创伤知情调查
- 批准号:
10548304 - 财政年份:2022
- 资助金额:
$ 68.75万 - 项目类别:
Implementation Research to Enhance Equity- Focused HIV Prevention in New York City
加强纽约市以公平为重点的艾滋病毒预防的实施研究
- 批准号:
10645068 - 财政年份:2021
- 资助金额:
$ 68.75万 - 项目类别:
Implementation Research to Enhance Equity- Focused HIV Prevention in New York City
加强纽约市以公平为重点的艾滋病毒预防的实施研究
- 批准号:
10460103 - 财政年份:2021
- 资助金额:
$ 68.75万 - 项目类别:
Implementation Research to Enhance Equity- Focused HIV Prevention in New York City
加强纽约市以公平为重点的艾滋病毒预防的实施研究
- 批准号:
10336187 - 财政年份:2021
- 资助金额:
$ 68.75万 - 项目类别:
Synthesizing Best Practice to Accelerate Access to Emerging HIV Prevention Modalities
综合最佳实践以加速获得新兴艾滋病毒预防方式
- 批准号:
10209311 - 财政年份:2020
- 资助金额:
$ 68.75万 - 项目类别:
Synthesizing Best Practice to Accelerate Access to Emerging HIV Prevention Modalities
综合最佳实践以加速获得新兴艾滋病毒预防方式
- 批准号:
10579917 - 财政年份:2020
- 资助金额:
$ 68.75万 - 项目类别:
Synthesizing Best Practice to Accelerate Access to Emerging HIV Prevention Modalities
综合最佳实践以加速获得新兴艾滋病毒预防方式
- 批准号:
10012324 - 财政年份:2020
- 资助金额:
$ 68.75万 - 项目类别:
Biomedical Prevention Adherence Dynamics in a High Priority Population
高优先人群的生物医学预防依从动态
- 批准号:
9558421 - 财政年份:2018
- 资助金额:
$ 68.75万 - 项目类别:
Full Research Project 1 Long-Term Adherence to Monitoring/Treatment in Underserved Asian Americans with Chronic HBV
完整研究项目 1 服务不足的亚裔美国人慢性乙型肝炎患者长期坚持监测/治疗
- 批准号:
10248418 - 财政年份:2018
- 资助金额:
$ 68.75万 - 项目类别:
相似海外基金
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
- 批准号:
10594350 - 财政年份:2023
- 资助金额:
$ 68.75万 - 项目类别:
Evaluating Centralizing Interventions to Address Low Adherence to Lung Cancer Screening Follow-up in Decentralized Settings
评估集中干预措施,以解决分散环境中肺癌筛查随访依从性低的问题
- 批准号:
10738120 - 财政年份:2023
- 资助金额:
$ 68.75万 - 项目类别:
Suubi-Mhealth: A mobile health intervention to address depression and improve ART adherence among Youth living with HIV (YLHIV) in Uganda
Suubi-Mhealth:一种移动健康干预措施,旨在解决乌干达艾滋病毒感染者 (YLHIV) 青少年的抑郁症问题并提高抗逆转录病毒疗法的依从性
- 批准号:
10526768 - 财政年份:2022
- 资助金额:
$ 68.75万 - 项目类别:
Suubi-Mhealth: A mobile health intervention to address depression and improve ART adherence among Youth living with HIV (YLHIV) in Uganda
Suubi-Mhealth:一种移动健康干预措施,旨在解决乌干达艾滋病毒感染者 (YLHIV) 青少年的抑郁症问题并提高抗逆转录病毒疗法的依从性
- 批准号:
10701072 - 财政年份:2022
- 资助金额:
$ 68.75万 - 项目类别:
A behavioral intervention for Black men who have sex with men and live with HIV to address intersectional stigma and improve antiretroviral therapy adherence
针对男男性行为且感染艾滋病毒的黑人男性进行行为干预,以解决交叉耻辱并提高抗逆转录病毒治疗的依从性
- 批准号:
10679092 - 财政年份:2021
- 资助金额:
$ 68.75万 - 项目类别:
A behavioral intervention for Black men who have sex with men and live with HIV to address intersectional stigma and improve antiretroviral therapy adherence
针对男男性行为且感染艾滋病毒的黑人男性进行行为干预,以解决交叉耻辱并提高抗逆转录病毒治疗的依从性
- 批准号:
10432133 - 财政年份:2021
- 资助金额:
$ 68.75万 - 项目类别:
A behavioral intervention for Black men who have sex with men and live with HIV to address intersectional stigma and improve antiretroviral therapy adherence
针对男男性行为且感染艾滋病毒的黑人男性进行行为干预,以解决交叉耻辱并提高抗逆转录病毒治疗的依从性
- 批准号:
10327065 - 财政年份:2021
- 资助金额:
$ 68.75万 - 项目类别:
Leveraging Technology to Address Access and Adherence to Conventional Hospital-Based Pulmonary Rehabilitation in Veterans with COPD
利用技术解决慢性阻塞性肺病退伍军人接受和坚持传统医院肺康复的问题
- 批准号:
10377366 - 财政年份:2019
- 资助金额:
$ 68.75万 - 项目类别:
Leveraging Technology to Address Access and Adherence to Conventional Hospital-Based Pulmonary Rehabilitation in Veterans with COPD
利用技术解决慢性阻塞性肺病退伍军人接受和坚持传统医院肺康复的问题
- 批准号:
10574496 - 财政年份:2019
- 资助金额:
$ 68.75万 - 项目类别:
Targeted interventions to address the multi-level effects of gender-based violence on PrEP uptake and adherence among adolescent girls and young women in Kenya
有针对性的干预措施,以解决性别暴力对肯尼亚少女和年轻妇女接受和坚持 PrEP 的多层面影响
- 批准号:
9403567 - 财政年份:2017
- 资助金额:
$ 68.75万 - 项目类别:














{{item.name}}会员




